SCHEMBL863219

SCHEMBL863219

CCC(C)(CC)C1CCC(C(=O)O)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.42
PLG P00747 1/20 0.42
PLAT P00750 1/20 0.42
HSD11B1 P28845 1/20 0.38
GABRP O00591 1/20 0.37
GABRD O14764 1/20 0.37
GABRA1 P14867 1/20 0.37
TSHR P16473 1/20 0.37
GABRB1 P18505 1/20 0.37
GABRG2 P18507 1/20 0.37
GABRB3 P28472 1/20 0.37
GABRA5 P31644 1/20 0.37
GABRA3 P34903 1/20 0.37
GABRA2 P47869 1/20 0.37
GABRB2 P47870 1/20 0.37
GABRA4 P48169 1/20 0.37
GABRE P78334 1/20 0.37
PMP22 Q01453 1/20 0.37
GABRA6 Q16445 1/20 0.37
GABRG1 Q8N1C3 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11029634 0.83 LMNA (0.42) LMNAPLGPLATHSD11B1GABRP
SCHEMBL11023629 0.83 LMNA (0.42) LMNAPLGPLATHSD11B1GABRP
SCHEMBL16205299 0.82 LMNA (0.41) LMNAPLGPLATHSD11B1GABRP
SCHEMBL881189 0.81 LMNA (0.43) LMNAPLGPLATHSD11B1GABRP
SCHEMBL14267477 0.79 GRM2 (0.35) LMNAAPLNRGRM2GRM3POLB
SCHEMBL1835961 0.78 GLA (0.50) LMNAPLGPLATHSD11B1GABRP
SCHEMBL3514603 0.78 GLA (0.50) LMNAPLGPLATHSD11B1GABRP
SCHEMBL503482 0.78 GLA (0.50) LMNAPLGPLATHSD11B1GABRP
SCHEMBL2675870 0.78 LMNA (0.48) LMNAPLGPLATHSD11B1GABRP
SCHEMBL18628984 0.76 GRM2 (0.37) LMNAPLGPLATHSD11B1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2766360-B1 SOLUBLE GUANYLATE CYCLASE ACTIVATORS BOEHRINGER INGELHEIM INT (DE) 2017-07-12 EP disclosed
US-8815857-B2 Soluble guanylate cyclase activators BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-08-26 US disclosed
US-8815857-B2 Soluble guanylate cyclase activators BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-08-26 US disclosed
US-20130203729-A1 SOLUBLE GUANYLATE CYCLASE ACTIVATORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-08-08 US disclosed
US-20130203729-A1 SOLUBLE GUANYLATE CYCLASE ACTIVATORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-08-08 US disclosed
US-20120073661-A1 PHOTOELECTRIC CONVERSION ELEMENT AND SOLAR CELL KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) 2012-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130203729-A1 SOLUBLE GUANYLATE CYCLASE ACTIVATORS GUCY1A2, GUCY1A1, GUCY1B1 LMNA 814/4885PLG 1733/4885PLAT 1280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.